A pharmaceutical plant with initial investment exceeding 2 billion roubles will be established in Tomsk, Siberia, by the company Amekhim, part of the Amedart Group, according to a statement from the Tomsk regional administration.
The project is planned in two phases. The first phase involves setting up a production facility for active pharmaceutical ingredients (APIs) within the “Tomsk” special economic zone. The second phase will see the construction of a plant for manufacturing finished dosage forms. The initial investments will exceed 2 billion rubles.
“The project will create a fundamentally new high-tech industry in the Tomsk region and provide an impetus for the development of related sectors and the formation of a sustainable ecosystem for training highly qualified personnel,” said Andrey Kolokoltsov, General Director of Amedart.
The statement noted that the local workforce for the new production site will be trained by educational institutions in the region. An agreement is already in place for graduates of the Siberian State Medical University to work at the Tomsk plant, with talks ongoing with other local universities.
The Amedart Group specialises in the development and production of anti-cancer drugs, anticoagulants, chelators, immunosuppressants, a calcimimetic, genetically engineered human insulins and insulin analogues, as well as medicines for treating HIV infection, renal failure, and multiple sclerosis. The group’s existing plant and R&D centre are located in the Technopolis Moscow special economic zone. The company’s portfolio includes over 150 medicines, and the facility’s production capacity exceeds 10 million drug packs per year.
